. ( PULM
) develops therapies for the treatment of pulmonary diseases. It came public above $20 in March 2014 and entered a severe downtrend that continued into the start of 2017, dropping to an all-time
low at 50-cents. The stock went vertical in early February, after meeting Nasdaq exchange compliance issues, and stalled following a 950K secondary offering at $3.50. It looks like new supply has been absorbed, favoring continued upside that could eventually reach double digits.